About this Journal Submit a Manuscript Table of Contents
International Journal of Hepatology
Volume 2012 (2012), Article ID 891516, 6 pages
http://dx.doi.org/10.1155/2012/891516
Review Article

Posttransplant Metabolic Syndrome

1Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA 23298-0341, USA
2Section of Hepatology, Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA 23298-0341, USA

Received 24 September 2012; Accepted 1 November 2012

Academic Editor: Koichi Tsuneyama

Copyright © 2012 M. Shadab Siddiqui and Richard K. Sterling. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” The Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Scopus
  2. E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey,” The Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002. View at Scopus
  3. M. R. Charlton, J. M. Burns, R. A. Pedersen, K. D. Watt, J. K. Heimbach, and R. A. Dierkhsing, “Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the united states,” Gastroenterology, vol. 141, no. 4, pp. 1249–1253, 2011. View at Publisher · View at Google Scholar
  4. F. I. Tellez-Avila, F. Sanchez-Avila, M. García-Saenz-de-Sicilia et al., “Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis,” World Journal of Gastroenterology, vol. 14, no. 30, pp. 4771–4775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. D. Stegall, G. Everson, G. Schroter, B. Bilir, F. Karrer, and I. Kam, “Metabolic complications after liver transplantation: diabetes, hypercholesterolemia, hypertension, and obesity,” Transplantation, vol. 60, no. 9, pp. 1057–1060, 1995. View at Scopus
  6. M. Laryea, K. D. Watt, M. Molinari et al., “Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events,” Liver Transplantation, vol. 13, no. 8, pp. 1109–1114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Bianchi, G. Marchesini, R. Marzocchi, A. D. Pinna, and M. Zoli, “Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression,” Liver Transplantation, vol. 14, no. 11, pp. 1645–1654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. D. Johnston, J. K. Morris, R. Cramb, B. K. Gunson, and J. Neuberger, “Cardiovascular morbidity and mortality after orthotopic liver transplantation,” Transplantation, vol. 73, no. 6, pp. 901–906, 2002. View at Scopus
  9. I. A. Hanouneh, A. E. Feldstein, A. J. McCullough et al., “The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation,” Liver Transplantation, vol. 14, no. 9, pp. 1287–1293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. D. S. Watt, R. A. Pedersen, W. K. Kremers, J. K. Heimbach, and M. R. Charlton, “Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study,” American Journal of Transplantation, vol. 10, no. 6, pp. 1420–1427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. P. Vogt, J. M. Henderson, W. D. Carey, and D. Barnes, “The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation,” Surgery, vol. 132, no. 4, pp. 775–780, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Perseghin, V. Mazzaferro, L. P. Sereni et al., “Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation,” Hepatology, vol. 31, no. 3, pp. 694–703, 2000. View at Scopus
  13. A. S. Petrides, C. Vogt, D. Schulze-Berge, D. Matthews, and G. Strohmeyer, “Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis,” Hepatology, vol. 19, no. 3, pp. 616–627, 1994. View at Scopus
  14. J. I. Moon, R. Barbeito, R. N. Faradji, J. J. Gaynor, and A. G. Tzakis, “Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up,” Transplantation, vol. 82, no. 12, pp. 1625–1628, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Reuben, “Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity,” Liver Transplantation, vol. 7, no. 11, supplement 1, pp. S13–S21, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Baid, A. B. Cosimi, M. L. Farrell et al., “Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal, relationship with hepatitis C virus allograft hepatitis, and impact on mortality,” Transplantation, vol. 72, no. 6, pp. 1066–1072, 2001. View at Scopus
  17. P. R. John and P. J. Thuluvath, “Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus,” Liver Transplantation, vol. 8, no. 8, pp. 708–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. B. J. Veldt, J. J. Poterucha, K. D. S. Watt et al., “Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C,” American Journal of Transplantation, vol. 9, no. 6, pp. 1406–1413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Y. Yoo and P. J. Thuluvath, “The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation,” Transplantation, vol. 74, no. 7, pp. 1007–1012, 2002. View at Scopus
  20. M. Navasa, J. Bustamante, C. Marroni et al., “Diabetes mellitus after liver transplantation: prevalence and predictive factors,” Journal of Hepatology, vol. 25, no. 1, pp. 64–71, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. S. G. Tueche, “Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding,” Transplantation Proceedings, vol. 35, no. 4, pp. 1466–1468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. K. C. Trail, T. M. McCashland, J. L. Larsen et al., “Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation,” Liver Transplantation and Surgery, vol. 2, no. 4, pp. 276–283, 1996. View at Scopus
  23. H. Schäcke, W. D. Döcke, and K. Asadullah, “Mechanisms involved in the side effects of glucocorticoids,” Pharmacology and Therapeutics, vol. 96, no. 1, pp. 23–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. D. L. Segev, S. M. Sozio, E. J. Shin et al., “Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials,” Liver Transplantation, vol. 14, no. 4, pp. 512–525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Weiler, I. Thrun, M. Hoppe-Lotichius, T. Zimmermann, I. Kraemer, and G. Otto, “Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial,” Transplantation, vol. 90, no. 12, pp. 1562–1566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. V. J. Canzanello, L. Schwartz, S. J. Taler et al., “Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506),” Liver Transplantation and Surgery, vol. 3, no. 1, pp. 1–9, 1997. View at Scopus
  27. E. M. Haddad, V. C. McAlister, E. Renouf, R. Malthaner, M. S. Kjaer, and L. L. Gluud, “Cyclosporin versus tacrolimus for liver transplanted patients,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005161, 2006. View at Scopus
  28. L. A. Øzbay, K. Smidt, D. M. Mortensen, J. Carstens, K. A. Jørgensen, and J. Rungby, “Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E β-cells,” British Journal of Pharmacology, vol. 162, no. 1, pp. 136–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. V. P. Houde, S. Brûlé, W. T. Festuccia et al., “Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue,” Diabetes, vol. 59, no. 6, pp. 1338–1348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Briaud, L. M. Dickson, M. K. Lingohr, J. F. McCuaig, J. C. Lawrence, and C. J. Rhodes, “Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells,” The Journal of Biological Chemistry, vol. 280, no. 3, pp. 2282–2293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J. E. Everhart, M. Lombardero, J. R. Lake, R. H. Wiesner, R. K. Zetterman, and J. H. Hoofnagle, “Weight change and obesity after liver transplantation: incidence and risk factors,” Liver Transplantation and Surgery, vol. 4, no. 4, pp. 285–296, 1998. View at Scopus
  32. J. Richards, B. Gunson, J. Johnson, and J. Neuberger, “Weight gain and obesity after liver transplantation,” Transplant International, vol. 18, no. 4, pp. 461–466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Wawrzynowicz-Syczewska, E. Karpińska, K. Jurczyk, Ł. Laurans, and A. Bororń-Kaczmarska, “Risk factors and dynamics of weight gain in patients after liver transplantation,” Annals of Transplantation, vol. 14, no. 3, pp. 45–50, 2009. View at Scopus
  34. S. Desai, J. C. Hong, and S. Saab, “Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management,” Liver International, vol. 30, no. 7, pp. 948–957, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Gisbert, M. Prieto, M. Berenguer et al., “Hyperlipidemia in liver transplant recipients: prevalence and risk factors,” Liver Transplantation and Surgery, vol. 3, no. 4, pp. 416–442, 1997. View at Scopus
  36. D. A. J. Neal, B. D. M. Tom, J. Luan et al., “Is there disparity between risk and incidence of cardiovascular disease after liver transplant?” Transplantation, vol. 77, no. 1, pp. 93–99, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Pfitzmann, N. C. Nüssler, M. Hippler-Benscheidt, R. Neuhaus, and P. Neuhaus, “Long-term results after liver transplantation,” Transplant International, vol. 21, no. 3, pp. 234–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. M. Dehghani, S. A. R. Taghavi, A. Eshraghian et al., “Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors,” Journal of Gastroenterology, vol. 42, no. 9, pp. 769–774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. J. Munoz, R. O. Deems, M. J. Moritz, P. Martin, B. E. Jarrell, and W. C. Maddrey, “Hyperlipidemia and obesity after orthotopic liver transplantation,” Transplantation Proceedings, vol. 23, no. 1, part 2, pp. 1480–1483, 1991. View at Scopus
  40. K. K. Lau, D. J. Tancredi, R. V. Perez, and L. Butani, “Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1506–1512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. V. Hulzebos, C. M. A. Bijleveld, F. Stellaard et al., “Cyclosporine A—induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation,” Liver Transplantation, vol. 10, no. 7, pp. 872–880, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Manzarbeitia, D. J. Reich, K. D. Rothstein, L. E. Braitman, S. Levin, and S. J. Munoz, “Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients,” Liver Transplantation, vol. 7, no. 2, pp. 93–99, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Roy, N. Kneteman, L. Lilly et al., “Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant,” Transplantation, vol. 82, no. 4, pp. 494–500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. J. D. Morrisett, G. Abdel-Fattah, and B. D. Kahan, “Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients,” Transplantation Proceedings, vol. 35, no. 3, supplement, pp. 143S–150S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. J. F. Trotter, M. E. Wachs, T. E. Trouillot et al., “Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus,” Liver Transplantation, vol. 7, no. 5, pp. 401–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. V. J. Canzanello, S. C. Textor, S. J. Taler et al., “Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation,” Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 1910–1917, 1995. View at Scopus
  47. C. Fernández-Miranda, M. Sanz, A. dela Calle et al., “Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation,” Transplant International, vol. 15, no. 11, pp. 556–562, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Rabkin, H. R. Rosen, C. L. Corless, and A. J. Olyaei, “Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients,” Transplantation Proceedings, vol. 34, no. 5, pp. 1557–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. J. M. Vieira Jr., I. L. Noronha, D. M. A. C. Malheiros, and E. A. Burdmann, “Cyclosporine-induced interstitial fibrosis and arteriolar TGF-β expression with preserved renal blood flow,” Transplantation, vol. 68, no. 11, pp. 1746–1753, 1999. View at Scopus
  50. W. R. Kim, J. J. Poterucha, M. K. Porayko, E. R. Dickson, J. L. Steers, and R. H. Wiesner, “Recurrence of nonalcoholic steatohepatitis following liver transplantation,” Transplantation, vol. 62, no. 12, pp. 1802–1805, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Contos, W. Cales, R. K. Sterling et al., “Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis,” Liver Transplantation, vol. 7, no. 4, pp. 363–373, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. L. G. Lim, C. L. Cheng, A. Wee et al., “Prevalence and clinical associations of posttransplant fatty liver disease,” Liver International, vol. 27, no. 1, pp. 76–80, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Seo, K. Maganti, M. Khehra et al., “De novo nonalcoholic fatty liver disease after liver transplantation,” Liver Transplantation, vol. 13, no. 6, pp. 844–847, 2007. View at Publisher · View at Google Scholar · View at Scopus